Loading...
Market
Will competitors introduce similar blood-based colon cancer tests by end of 2025?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Healthcare industry reports or announcements from competitive companies
Story
Independent FDA Panel Recommends Approval of Guardant Health's Blood-Based Colon Cancer Test
May 23, 2024, 06:31 PM
Advisers to the U.S. Food and Drug Administration (FDA) have recommended the approval of Guardant Health's blood-based test for detecting colorectal cancer. If approved, this will be the first blood screening test for colorectal cancer that meets the requirements for Medicare reimbursement. The recommendation by an independent panel marks a significant step towards FDA approval in the U.S., potentially improving early detection and treatment of colon cancer.
View original story
Similar markets
No competitors • 33%
1-2 competitors • 33%
3 or more competitors • 33%
No competitors respond • 25%
1-2 competitors respond • 25%
3-5 competitors respond • 25%
More than 5 competitors respond • 25%
Yes • 50%
No • 50%
FDA (USA) • 33%
EMA (Europe) • 33%
WHO • 33%
EU • 33%
Asia • 33%
South America • 33%